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ORIGINAL ARTICLE – HEPATOBILIARY TUMORS
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ABSTRACT
Background. Lymph node metastases on routine histology
are a strong negative predictor for survival after resection of
hilar cholangiocarcinoma. Additional immunohistochem-
istry can detect lymph node micrometastases in patients who
are otherwise node negative, but the prognostic value is
unsure. The objective of this study was to assess the effect on
survival of immunohistochemically detected lymph node
micrometastases in patients with node-negative (pN0) hilar
cholangiocarcinoma on routine histology.
Methods. Between 1990 and 2010, a total of 146 patients
underwent curative-intent resection of hilar cholangiocar-
cinoma with regional lymphadenectomy at two university
medical centers in the Netherlands. Ninety-one patients
(62 %) without lymph node metastases at routine histology
were included. Micrometastases were identified by multi-
ple sectioning of all lymph nodes and additional
immunostaining with an antibody against cytokeratin 19
(K19). The association with overall survival was assessed
in univariable and multivariable analysis. Median follow-
up was 48 months.
Results. Micrometastases were identified in 16 (5 %) of
324 lymph nodes, corresponding to 11 (12 %) of 91
patients. There were no differences in clinical variables
between K19 lymph node-positive and -negative patients.
Five-year survival rates in patients with lymph node
micrometastases were significantly lower compared to
patients without micrometastases (27 vs. 54 %, P = 0.01).
Multivariable analysis confirmed micrometastases as an
independent prognostic factor for survival (adjusted Hazard
ratio 2.4, P = 0.02).
Conclusions. Lymph node micrometastases are associated
with worse survival after resection of hilar cholangiocar-
cinoma. Immunohistochemical detection of lymph node
micrometastases leads to better staging of patients who
were initially diagnosed with node-negative (pN0) hilar
cholangiocarcinoma on routine histology.
Hilar cholangiocarcinoma, also known as Klatskin
tumor, is a malignancy originating from the biliary
epithelium at the confluence of the left and right hepatic
duct.1 Cure can only be achieved by complete surgical
resection of the tumor, consisting of extrahepatic bile duct
resection with a partial hepatectomy, lymphadenectomy of
the hepatoduodenal ligament, and occasionally portal vein
or hepatic artery resection.2–4 Despite recent improvements
in surgical techniques, the prognosis after curative resec-
tion remains poor, with reported 5-year survival rates
below 40 %.2,4–6
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Regional lymph node status is known to be an important
predictor of survival after resection.2,4,5,7,8 However, even
patients without lymph node metastases at postoperative
pathologic examination frequently develop tumor recur-
rence. One possible explanation is the presence of
micrometastases in the lymph nodes, resulting in under-
staging of the disease.
Conventional routine histologic examination of the
resected specimen includes single sectioning of the lymph
nodes with hematoxylin and eosin (H&E) staining. This
procedure may underestimate the incidence of nodal
metastases. Additional immunohistochemical staining with
cytokeratin antibodies may facilitate the detection of small
tumor deposits in lymph nodes (micrometastases). In recent
years, a number of studies have shown the clinical signif-
icance of immunohistochemically detected lymph node
micrometastases in a variety of tumors, including those of
breast, lung, esophagus, stomach, colon, and gallblad-
der.9–21 Regarding hilar cholangiocarcinoma, contradicting
reports have been published.22–24
This study was undertaken to further investigate the
significance of multiple lymph node sectioning and addi-
tional immunohistochemical detection of micrometastases
on the survival of patients who were initially classified as
having lymph node-negative (pN0) hilar cholangiocarci-
noma on the basis of conventional histologic examination.
METHODS
Patients and Operation
Between January 1990 and July 2010, a total of 146
patients underwent a curative-intent resection and system-
atic lymph node dissection of the hepatoduodenal ligament
for hilar cholangiocarcinoma at two university medical
centers in the Netherlands. Fifty-six patients were treated at
the University Medical Center Groningen (UMCG), and 90
were treated at the Academic Medical Center Amsterdam
(AMC). In 91 (62 %) of these patients, no lymph node
metastases were detected by conventional histologic
examination (H&E staining) of the surgical specimen.
There were 49 male and 42 female patients. Mean age was
62 ± 9 years (range 36–78 years).
All patients underwent extrahepatic bile duct resection
with lymphadenectomy of the liver hilum, in most cases in
combination with (extended) hemihepatectomy. Standard
regional lymph node dissection consisted of an exploration
of the hepatoduodenal ligament and skeletonization of the
portal vein and hepatic artery after the distal common bile
duct was cut at the level of the pancreatic head and dis-
sected free. In accordance with the American Joint
Committee on Cancer (AJCC; 7th edition), lymph nodes at
the following locations were defined as regional: along the
cystic duct, common bile duct, proper hepatic artery, and
portal vein.25 Routine dissection of more distant lymph
nodes was not performed. However, suspected distant
lymph nodes (N2) were sampled via biopsy, and the
operation was aborted if intraoperative frozen section
analysis of these samples showed tumor cells.
The majority of patients (91 %) underwent a concomi-
tant partial hepatectomy. Left hemihepatectomy (either
extended or not) was performed in 38 patients (42 %) and
(extended) right hemihepatectomy was performed in 35
patients (38 %). Ten patients (11 %) underwent only con-
comitant segment 4 resection. Portal vein resection and
reconstruction was undertaken in 18 patients (20 %), and
arterial resection and reconstruction was undertaken in 2
patients (2 %). One patient underwent combined arterial
and portal venous reconstruction. Tumors were staged
according to the tumor, node, metastasis classification
system as proposed by the AJCC.25 A total of 324 lymph
nodes were retrieved from 91 surgical specimens. On all
lymph nodes, additional immunohistochemical staining of
cytokeratin 19 (K19) was performed.
None of the patients in either institute received post-
operative chemotherapy or radiotherapy because this is not
recommended in the Dutch guidelines for bile duct
carcinoma.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue blocks of the
lymph nodes were retrieved from the tissue archives of the
departments of pathology in the AMC and UMCG. Four
new levels of each lymph node with a distance of 250 lm
between the levels were investigated. Two 4 lm thick
sections of each level were cut serially. One section was
stained with H&E and one with an antibody against K19
(dilation 1:100, clone RCK108; Dako, Glostrup, Denmark).
All staining procedures were performed in the UMCG. The
K19 staining was performed using a Ventana Benchmark
Ultra automated stainer (Ventana Medical Systems, Tuc-
son, AZ, USA) after pretreatment with protease.
Micrometastases were defined as cells detected by
immunostaining with morphologic features of adenocarci-
noma. H&E and K19 immunolabeled slides were
investigated by two experienced pathologists (ASHG and
JJD) blinded to the demographic and clinicopathologic
features of patients.
End Points
The effect of micrometastases was assessed in terms of
patient survival and time to recurrence. Patients who died
during postoperative hospital admission were excluded
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from the analyses because they were unlikely to have died
from recurrent disease. Patient survival was determined
from the time of surgery to the time of death or most recent
follow-up (March 17, 2014). No patient was lost to follow-
up. The median follow-up among survivors was 52 months
(range 8 months to 20 years).
Recurrences were defined as any new lesion on imaging
that was highly suspicious for recurrence of hilar cholan-
giocarcinoma. Pathologic confirmation was often obtained
but was not required. Recurrences at the liver resection
margin, distal bile duct remnant, hepaticojejunostomy, or
elsewhere in the liver hilum were classified as local
recurrences. All other recurrences were classified as dis-
tant. Time to recurrence was measured from the time of
surgery to the time of the first recurrence. Patients who had
no observed recurrence were censored at the time of last
follow-up, and patients who died from other causes before
developing a recurrence were censored at the time of death.
Statistical Analysis
Patient data and baseline characteristics were retro-
spectively collected in a database, and statistical analyses
were carried out by SPSS Statistics software (IBM,
Armonk, New York, USA). Continuous variables were
expressed as mean ± SD. Categorical variables were
expressed as numbers and percentages. Comparison of
means was performed with Student’s t test for independent
samples. Comparison of categorical variables was per-
formed with the v2 test or Fisher’s exact probability test.
Univariable analyses were conducted for patient survival
and time to recurrence by Kaplan–Meier estimates of sur-
vival probabilities and the log-rank test for comparisons.
A Cox proportional hazard regression model was used to
analyze associations with patient survival in multivariable
analysis, including all factors with a P value of less than
0.10 in univariable analysis. Because AJCC pT1 stage was
considered a potential confounder, we a priori included this
variable in the Cox model. P values were two sided, and
values of less than 0.05 were considered statistically
significant.
RESULTS
Micrometastases were detected in 16 (5 %) of 324
lymph nodes and in 11 (12 %) of 91 patients who were
initially considered lymph node negative by conventional
histologic examination (Fig. 1). The K19 labeling clearly
highlighted the adenocarcinoma foci and confirmed their
biliary origin.
Postoperative death during hospital admission (in-hos-
pital mortality) occurred in 11 (12 %) of 91 patients, who
were subsequently excluded from the survival analyses. In-
hospital mortality occurred only in the group without
micrometastases (range 8–80 days). Clinicopathologic
details of the remaining 80 patients with and without lymph
node micrometastases are shown in Table 1. There were no
statistically significant differences between the two groups.
During postoperative follow-up, 49 (61 %) of 80 patients
died. At the end of follow-up, 31 patients were alive, two
of whom were diagnosed with disease recurrence.
SURVIVAL ANALYSIS
The survival rates for patients were calculated according
to lymph node status. We defined three groups: patients
with lymph node (macro)metastases detected at routine
H&E examination (pN1); patients with lymph node
micrometastases detected with multiple sectioning and K19
staining (pN0 with micrometastases); and patients without
lymph node micrometastases (pN0 without micrometas-
tases). Five-year survival rates in patients without lymph
node micrometastases were significantly higher compared
A
B
FIG. 1 Cytokeratin 19-positive metastatic tumor cells in regional
lymph nodes from resected hilar cholangiocarcinoma specimens.
a Micrometastases consisting of two small tumor glands (original
magnification, 94). b Micrometastases consisting of single tumor
cells (arrow; original magnification, 94)
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to the other groups (P\ 0.001) (Fig. 2). There was a sig-
nificant difference in 5-year survival between patients with
and without micrometastases (27 vs. 54 %, P = 0.01), but
not between patients with micro- and macrometastases (27
vs. 15 %, P = 0.54).
RECURRENCE
During the study period, 30 (38 %) of 80 patients devel-
oped disease recurrence (local recurrence in 21 patients and
distant metastases in 9 patients). Figure 3 presents the esti-
mated cumulative probability of recurrence over time
according to the presence or absence of micrometastases. At
5-year follow-up, the estimated probability of recurrence
was 65 % in the group with micrometastases, versus 33 % in
patients without micrometastases (P = 0.06).
Next, the relationship between lymph node
micrometastases and pattern of recurrence was ana-
lyzed. There was a twofold higher percentage of distant
site recurrences in the group with micrometastases
compared to the group without micrometastases (18 vs.
9 %), but this did not reach statistical significance
(P = 0.40).
ANALYSIS OF PROGNOSTIC FACTORS
IN PATIENTS WITH PN0 DISEASE
Prognostic factors for survival were identified using
univariable analyses (Table 2). Two variables—micro-
scopic resection margin status (P = 0.09) and lymph node
micrometastases (P = 0.01)—were identified as predictors
for survival. These two variables were included in a mul-
tivariable Cox regression analysis, together with AJCC pT
stage, because this was a priori considered a possible
confounding variable. Only the presence of micrometas-
tases was identified as an independent predictive factor for
survival in patients with pN0 hilar cholangiocarcinoma
(Hazard ratio 2.43, 95 % confidence interval 1.16–5.10)
(Tables 2).
DISCUSSION
Lymph node metastases have been repeatedly identified
as an important prognostic factor for survival after resec-
tion of hilar cholangiocarcinoma.2,5,26 This has also been
the experience of the two centers participating in this
study.4,7 The current study was undertaken to improve
TABLE 1 Clinicopathologic characteristics of patients after curative-intent resection for hilar cholangiocarcinoma with and without lymph
node micrometastases
Characteristic Lymph node micrometastases P
Absent (n = 69) Present (n = 11)
Mean age in years (±SD) 61 ± 10 59 ± 6 0.40
Gender male/female 37/32 5/6 0.75
Type of hepatectomy
Left 25 4 0.90
Extended left 6 0
Right 5 1
Extended right 17 4
Only segment 4 resection 9 1
No liver resection 7 1
pT stagea





Microscopic resection margin positive 20 (29 %) 4 (36 %) 0.73
Perineural invasion positive 39 (57 %) 8 (73 %) 0.31
Complication rate grade III or IVb 24 (35 %) 4 (36 %) 0.92
Mean no. of dissected lymph nodes per patient 4 5 0.18
Patients with in-hospital mortality (n = 11) were excluded from analysis
a According to American Joint Committee on Cancer staging manual, 7th edition
b According to Clavien-Dindo classification of surgical complications. Grade V (in-hospital mortality) was excluded
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tumor staging by identifying lymph node micrometastases
in the pN0 group. To this end, we applied rigorous multiple
sectioning of the lymph node tissue blocks to achieve
deeper levels, investigated several levels of each lymph
node, and increased the sensitivity of tumor cell identifi-
cation by K19 immunolabeling. This method is a slight
modification of the histopathologic investigation of sen-
tinel nodes in other types of cancer (e.g., breast cancer and
melanoma). Using this technique, micrometastases were
detected in 5 % of the collected lymph nodes, which
related to 12 % of the 91 patients who were initially
characterized as pN0 on the basis of conventional histo-
logic examination of the surgical resection specimen with
H&E staining. Survival in the group with lymph node
micrometastases was significantly worse compared to
patients without micrometastases and comparable to
patients with pN1 disease. There was a trend toward earlier
tumor recurrence in patients with micrometastases,
although this did not reach statistical significance (Fig. 3).
Remarkably, the presence of lymph node micrometastases
was found to be a stronger predictor than the level of tumor
invasion (T stage) and microscopic resection margin status
(Table 2). The same phenomenon was previously observed
in a study by Yonemori et al.24 A possible explanation is
that lymph node micrometastases represent a more
aggressive biologic behavior of the tumor, similar to lymph
node metastases found on routine histology.
Only three previous studies, all from Japan, have
addressed the effect of lymph node micrometastases on
survival in hilar cholangiocarcinoma, and these studies
have shown contradictory results.22–24 Yonemori et al.
found lymph node micrometastases to be of influence on
the survival in a heterogeneous group of 151 patients with
biliary cancer (including gallbladder cancer, intrahepatic
cholangiocarcinoma, and ampullary cancer).24 A subgroup
analysis of patients with hilar bile duct cancer only
revealed lymph node micrometastases in 4 % of the
investigated nodes and in 22 (27 %) of 83 patients, but no
significant impact on survival was found. Similarly, Tojima
et al. detected lymph node micrometastases in 13 (1.4 %)
of 954 examined lymph nodes, corresponding to 11 (24 %)
of 45 patients; they also concluded that lymph node
micrometastases had no effect on postoperative survival.23
In contrast, Taniguchi et al. found lymph node
micrometastases in 14 (3.3 %) of 423 lymph nodes and 11
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FIG. 2 Survival after resection
for hilar cholangiocarcinoma
according to lymph node status.
Patients with in-hospital
mortality were excluded from
analysis. pN0 without
micrometastases versus pN0
with micrometastases: P = 0.01
(log-rank test). pN0 with
micrometastases versus pN1:
P = 0.54 (log-rank test)
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lower survival rate in patients with lymph node
micrometastases.22
The current study is the first Western series in which the
incidence of lymph node micrometastases and its influence
on survival was investigated and presents the largest cohort
published to date, consisting of 91 pN0 patients. There are
some differences between our series and those reported in
literature.
First, we found micrometastases in 12 % of the patients
who were initially considered node negative on routine
histologic examination. This is slightly less than the
24–39 % reported in the three Japanese series.22–24 The
number of serial sections that were cut from the archival
tissue blocks can be an explanation for this difference. In
our study, four additional sections were performed, with a
distance of 250 lm between consecutive levels, compared
to five to eight serial sections reported in the three Japanese
studies.22–24 We believe that with our technique all tumor
cell clusters in the lymph nodes were detected. Some
authors state that 200 lm should be the maximum distance
between consecutive levels.27 When adopting this strategy,
we should have investigated five instead of four levels, but
it is questionable whether this extra level would have
significantly increased the sensitivity of the procedure. To
illustrate this, in the Japanese series, the percentage of
patients in whom micrometastases were detected did not
linearly rise with increased sectioning (24 % in the study
with five serial sections, vs. 27 % in the study with eight
serial sections).23,24 Recent studies of cancer of the breast,
lung, stomach, and colorectum have classified metastatic
tumor cells by size into micrometastases ([0.2 mm) and
isolated tumor cells (B0.2 mm).23,24,28–31 In our series, this
type of further differentiation was not possible because in
all cases metastatic tumor cells were larger than 0.2 mm in
size (between 0.2 and 0.4 mm). Increased sectioning would
probably have resulted in increased detection of isolated
tumor cells. However, the significance of isolated tumor
cells remains a subject of debate, even in breast cancer,
where this issue has been studied more than in any other
type of cancer.32
Second, lymphadenectomy in our population resulted in
a mean of 4 lymph nodes per patient (range 1–16), which is
less than the 10–20 nodes per patient reported in the
Japanese series.22–24 However, this is in line with other
Western series and in accordance with the AJCC/Interna-
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FIG. 3 Cumulative probability
of recurrence after resection for
hilar cholangiocarcinoma in
patients classified as pN0 based
on routine histologic
examination, with or without




(n = 11) were excluded from
analysis; P = 0.06 (log-rank
test)
S1112 H. T. J. Mantel et al.
that at least 3 lymph nodes should be collected for adequate
staging of hilar cholangiocarcinoma.33,34 The difference in
number of collected lymph nodes between our study and
the Japanese series can be explained by the variation in
extent of the lymphadenectomy. In contrast to the Japanese
experience, it is not routine surgical practice in the
Netherlands to perform standard removal of N2 nodes
(para-aortic, caval vein, and superior mesenteric). An N2
node is only removed when macroscopically suspicious
and is then sent for intraoperative frozen sections analysis.
The surgical procedure is aborted when frozen section
analysis shows metastatic tumor cells.
The in-hospital mortality rate in the present study was
15 % for the entire group of patients and 12 % in the group
with pN0 disease. Some series report a lower mortality
rate, but in these series, patients who only underwent
extrahepatic bile duct resection, without concomitant par-
tial liver resection, were also included.5 Most of our
patients ([90 %) underwent partial hepatectomy in addi-
tion to extrahepatic bile duct resection. Indeed, the
postoperative mortality rate in our population is compara-
ble to the mortality rate of 10–11 % described in other
series in which partial hepatectomy was part of the surgical
procedure.34–36
TABLE 2 Univariable analysis of survival in patients with hilar cholangiocarcinoma classified as pN0 based on routine histologic examination
Variable No. patients 5-year survival (%) P
Univariable analysis
Age
\60 year 30 (38 %) 43 0.38
C60 year 50 (62 %) 55
Sex
Male 42 (53 %) 49 0.71
Female 38 (47 %) 52
Type of hepatectomya
Left 45 (63 %) 50 0.40
Right 27 (37 %) 40
pT stageb
T1 14 (17 %) 71 0.37
T2a and 2b 52 (66 %) 47
T3 and 4 14 (17 %) 41
Perineural invasion
Negative 33 (41 %) 47 0.60
Positive 47 (59 %) 53
Lymph node micrometastases
Negative 69 (86 %) 54 0.01
Positive 11 (14 %) 27
Microscopic resection margin status
Negative 56 (70 %) 56 0.09
Positive 24 (30 %) 38




T2a and T2b 1.55 0.64–3.75 0.33
T3 and T4 1.25 0.42–3.76 0.69
Lymph node micrometastases 2.43 1.16–5.10 0.02
Microscopic resection margin status 1.54 0.85–2.80 0.16
Patients with in-hospital mortality were excluded from analysis
a Patients without concomitant liver resection (n = 8) were excluded from analysis
b According to American Joint Committee on Cancer staging manual, 7th edition
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In the current study, micrometastases were detected by
multiple sectioning of the lymph nodes together with K19
immunohistochemistry. In our opinion, application of both
methods is important to detect micrometastases. In some
cases, micrometastases were evident even without K19
staining (Fig. 1a) but would not have been found if additional
sectioning had been omitted. In other cases, K19 labeling was
necessary to highlight the small micrometastases.
In conclusion, this study shows that the presence of lymph
node micrometastases in patients with otherwise node-neg-
ative hilar cholangiocarcinoma has a negative effect on
survival. The technique of multiple lymph node sectioning
together with K19 immunostaining results in improved
staging of patients with hilar cholangiocarcinoma.
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